Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade 1-2 cytokine release syndrome (CRS), though severe cases (grade 3) were ...
AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...
AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...
Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...
JSC did not participate in High Court case brought by liquidators of GTLK Europe DAC and GTLK Europe Capital DAC in case relating to 37 aircraft worth over €1.85bn ...
Oct. 21, 2024 — Scientists paint a compelling picture of what happened the day the S2 meteorite crashed into Earth 3.26 billion years ... Weather-Changing El Nino Oscillation Is at Least 250 ...